These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 15899070)

  • 21. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    Mortimer JE; Urban JH
    Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors in the treatment of early and advanced breast cancer.
    Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
    Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initialization of adjuvant hormonal treatment for breast cancer.
    Martínez Guisado A; Sánchez Muñoz A; de la Cabeza Lomas Garrido M; Ruíz Borrego M; Bayo Calero J; de Toro Salas R; González Mancha R; de la Haba Rodríguez J; Alba Conejo E
    Adv Ther; 2011 Sep; 28 Suppl 6():66-84. PubMed ID: 21922396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving uses of hormonal agents for breast cancer therapy.
    Cummings FJ
    Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Chung CT; Carlson RW
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitors and breast cancer prevention.
    Litton JK; Arun BK; Brown PH; Hortobagyi GN
    Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
    Angiolini C
    Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.